v3.25.4
EQUITY (Tables)
 12 Months Ended
Dec. 31, 2025
Equity [Abstract]  
Schedule of Stock Options
Stock option activity for the years ended December 31, 2025, 2024 and 2023 is summarized as follows:

 202520242023
(Shares in thousands)Number of
shares		Weighted
average
exercise
price		Number of
shares		Weighted
average
exercise
price		Number of
shares		Weighted
average
exercise
price
Options outstanding, beginning of year1.2 $84.51 1.3 $71.83 1.8 $62.59 
Granted0.3 83.70 0.2 140.62 0.2 81.79 
Exercised(0.2)42.57 (0.3)52.19 (0.7)51.04 
Options outstanding, end of year1.3 $89.66 1.2 $84.51 1.3 $71.83 
Options exercisable, end of year0.8 $84.92 0.8 $71.76 0.9 $63.08 
Schedule of Options Outstanding
Options outstanding under the Company’s stock plans at December 31, 2025 are summarized as follows:
(Shares in thousands)Options outstandingOptions exercisable
Range of exercise pricesNumber
outstanding		Weighted
average
remaining life
in years		Weighted-
average
exercise
price		Number
exercisable		Weighted
average
exercise
price
$0.00 to $70.30
0.3 1.9 years$56.73 0.3 $56.73 
$70.31 to $80.71
0.3 4.8 years79.57 0.2 79.61 
$80.72 to $98.11
0.4 4.5 years90.93 0.2 96.01 
$98.12 to $140.62
0.3 4.1 years134.68 0.1 131.44 
1.3 4.0 years$89.66 0.8 $84.92 
Schedule of Weighted Average Assumptions The following table presents the weighted-average assumptions used in the valuation and the resulting weighted-average fair value per option granted for the years ended December 31, 2025, 2024 and 2023:
Employee stock options:202520242023
Volatility47.0 %47.6 %46.5 %
Risk-free interest rate3.9 %4.4 %3.7 %
Dividend yield0.5 %0.3 %0.5 %
Expected life (years)4.74.64.7
Weighted average fair value per option$35.70 $61.94 $34.40 
Schedule of Restricted Stock Activity A summary of the Company’s restricted stock unit activity for the years ended December 31, 2025, 2024 and 2023 is presented in the following table:
202520242023
(Shares in thousands)
Number
of
shares		Weighted
average
grant date
fair value		Number
of
shares		Weighted
average
grant date
fair value		Number
of
shares		Weighted
average
grant date
fair value
Unvested, beginning of year1.1 $111.81 1.0 $89.08 0.9 $90.37 
Granted0.7 85.11 0.5 138.44 0.6 80.45 
Vested(0.4)108.75 (0.3)86.92 (0.4)78.17 
Forfeited(0.1)104.55 (0.1)101.31 (0.1)89.23 
Unvested, end of year1.3 98.40 1.1 111.81 1.0 89.08 
Schedule of Allocation of Share Based Compensation Expense The following table summarizes the allocation of share-based compensation expense related to employee stock options, restricted stock awards, performance-based restricted stock awards and grants under the employee stock purchase plan for the years ended December 31, 2025, 2024 and 2023:
(In thousands)202520242023
Cost of sales$12.7 $11.1 $8.9 
Engineering, research and development expenses10.6 10.5 8.0 
Selling, general and administrative expenses46.0 44.3 44.5 
Share-based compensation expense$69.3 $65.9 $61.4 
Tax benefit13.6 13.0 12.5 
Share-based compensation expense, net of tax$55.7 $52.9 $48.9